Live · updated just now · 27 stories in 24h

← Stream
Stocks & Indices Unverified First seen

FDA declines to approve Summit's ivonescimab lung cancer drug

Investor's Business Daily reported that the FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab, saying it failed to show a statistically significant survival benefit. A follow-up IBD post said Summit's stock crashed Monday after the FDA rejected the Merck-rivaling drug.

Why “Unverified”

  • Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 2 posts · evidence score 52/100. How labels work

What the sources claim

  1. The FDA did not approve Summit Therapeutics' ivonescimab because it failed to show a statistically significant survival benefit.

    “failed to show a statistically significant survival benefit”
    Investor's Business Daily
  2. Summit Therapeutics' stock crashed Monday after the FDA rejected ivonescimab.

    “Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected”
    Investor's Business Daily

Sources

More in Stocks & Indices

All Stocks & Indices stories →

Embed this page

Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-16 15:10 UTC. Labels are computed from the sources, not by the model.